Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Acquires Microbiological Testing Firm

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that it has acquired Trek Diagnostic Systems from Magellan Biosciences for an undisclosed amount.

Trek makes blood culture, microorganism identification, and antibiotic-susceptibility testing products for the pharmaceutical and clinical lab markets. The firm is based near Cleveland, has 150 employees, and had full-year 2010 revenues of $34 million.

"The range of products manufactured by Trek ideally complements our existing portfolio of microbiological testing technologies," Thermo Fisher President and CEO Marc Casper said in a statement.

Trek will be integrated into Thermo Fisher's Analytical Technologies segment.

The acquisition is the latest in a string for Thermo Fisher. The firm is in the process of acquiring allergy and autoimmune diagnostics firm Phadia for $3.5 billion, and it recently purchased chromatography firm Dionex for $2.1 billion.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.